Clinical Trial: A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540338) titled 'A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder' on March 17.

Brief Summary: The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder. The main questions this study aims to answer are:

* How safe is AL001 when compared to lithium carbonate?

* How is AL001 broken down in the brain and body compared to lithium carbonate?

Participants...